There is substantial preclinical evidence suggesting that sodium thiosulfate (STS) could be a potential and important chronic medication for the treatment of cardiovascular diseases (CVDs). To date, STS is only administered intravenously in cases of cyanide poisoning, to manage chemotherapy side effects, and off-label for calciphylaxis. An oral application has not yet been established, as existing tablet and liquid formulations have shown insufficient bioavailability.
This invention involves a unique, inventive, and patented tablet formulation that allows STS to be administered orally in an effective and safe manner, enabling chronic treatment with STS. This has been demonstrated in vitro. The VFF plan represents the next step toward achieving proof of concept for STS as a treatment for CVDs through a clinical study in patients with Raynaud's syndrome.
